Podofilox is an antimitotic prescription medicine. (Antimitotic means blocking cell growth by stopping cell division.) Podofilox comes in two forms: a gel and a solution. The gel form of podofilox is approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of external genital warts and perianal warts. The solution form of podofilox is FDA-approved for the topical treatment of external genital warts.
External genital warts and perianal warts are caused by the human papillomavirus (HPV). HPV is an opportunistic infection. An opportunistic infection is an infection that occurs more frequently or is more severe in people with weakened immune systems—such as those infected with HIV—than in people with healthy immune systems.
The Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, prepared by the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association of the Infectious Diseases Society of America (IDSA-HIVMA), include recommendations on the HIV-related use of podofilox to treat external genital warts caused by HPV.
The above paragraph may not include all of the HIV-related uses of podofilox recommended in the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Some recommended uses, such as uses in certain rare circumstances, may have been omitted.
Before taking podofilox, tell your health care provider:
Ask your health care provider about possible side effects from podofilox. Your health care provider will tell you what to do if you have side effects.
Take podofilox according to your health care provider’s instructions. Your health care provider will tell you how much podofilox to use and when to use it. Before you start podofilox and each time you get a refill, read any printed information that comes with your medicine.
More information about podofilox is available:
Last Reviewed: June 11, 2015
Last Updated: June 11, 2015